Home
Storia in 1 fonti
Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Goup CEO
As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America and Europe through sophisticated product offerings, Cipla is also intensifying its focus on managing chronic conditions such as diabetes and heart diseases in India.
Raccontata da
economictimes.indiatimes.com
Timeline cronologica
- ·
Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Goup CEO
As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America…
- ·
Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEO
As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to broaden its footprint in North America…
- ·
Cipla is aiming for 40-50 global product filings in three years, says MD Achin Gupta
Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant global product filings over the next…